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The Global Meningococcal Initiative (GMI) is a global expert group that includes scientists, clinicians, and
public health officials with a wide range of specialties. The purpose of the Initiative is to promote the glo-
bal prevention of meningococcal disease (MD) through education, research, and cooperation. The first
Asia-Pacific regional meeting was held in November 2014. The GMI reviewed the epidemiology of MD,
surveillance, and prevention strategies, and outbreak control practices from participating countries in
the Asia-Pacific region. Although, in general, MD is underreported in this region, serogroup A disease is
most prominent in low-income countries such as India and the Philippines, while Taiwan, Japan, and
Korea reported disease from serogroups C, W, and Y. China has a mixed epidemiology of serogroups A,
B, C, and W.
Perspectives from countries outside of the region were also provided to provide insight into lessons
learnt. Based on the available data and meeting discussions, a number of challenges and data gaps were
identified and, as a consequence, several recommendations were formulated: strengthen surveillance;
improve diagnosis, typing and case reporting; standardize case definitions; develop guidelines for out-
break management; and promote awareness of MD among healthcare professionals, public health offi-
cials, and the general public.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5856
2. Meeting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58562.1. Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5856
2.2. Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5856id; DNA,
nters for
/Men W,
iological
hilippine
Enwere),
5856 R. Borrow et al. / Vaccine 34 (2016) 5855–58623. Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5856
3.1. Overview of MD across the globe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58563.1.1. Latin America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5856
3.1.2. United States. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5857
3.1.3. Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5857
3.1.4. Africa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58573.2. Overview of MD in the Asia-Pacific region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5857
3.2.1. China . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5857
3.2.2. India . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5858
3.2.3. Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5860
3.2.4. Republic of Korea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5860
3.2.5. The Philippines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58613.3. Achievements and remaining challenges in the Asia-Pacific region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5861
3.4. Recommendations for the control and prevention of meningococcal disease in the Asia-Pacific region . . . . . . . . . . . . . . . . . . . . . . . . . 58614. Summary and conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5862
Conflict of interest statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5862
Author contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5862
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5862
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58621. Introduction
Neisseria meningitidis is a leading cause of meningitis and sep-
ticemia and is estimated to cause more than 1.2 million cases of
invasive meningococcal disease (MD) and 135,000 deaths each
year across the globe [1,2]. MD is associated with substantial mor-
bidity and high fatality rates (10–20%, although higher rates of
30% have been reported for serogroup W alone) [3,4]. However,
in many countries in the Asia-Pacific region, the true burden of dis-
ease is unknown because the epidemiology of MD is not well
described [5]. Indeed, in countries such as the Republic of Korea
and Japan, which have frequently reported a low incidence of
MD, the disease is not considered a high healthcare priority.
The Global Meningococcal Initiative (GMI) was established in
2009 to promote the global prevention of MD through education,
research and cooperation. It comprises some 50 scientists and clin-
icians from around the world with expertise in meningococcal
immunology, epidemiology, public health, and vaccinology. A
regional meeting of the GMI was convened with the goal of gaining
a better understanding of MD in the Asia-Pacific region. This article
summarizes the discussions that took place at the meeting and
outlines the regional recommendations for the control and preven-
tion of MD based on the available data and regional expert opinion.2. Meeting
2.1. Overview
The meeting, the first to be convened in the Asia-Pacific region,
was held in Incheon, Republic of Korea, on 20–21 November 2014.
The aim of the meeting was to provide an update on the epidemi-
ology of MD in this region, with a particular emphasis on the recent
outbreaks that have been reported in a number of Asia-Pacific
countries and the control strategies that have been implemented.
Members from countries outside the region were also invited to
share their experiences and the lessons learned from their vaccina-
tion and outbreak programs (e.g., reactive quadrivalent [ser-
ogroups A, C, W and Y] meningococcal conjugate vaccination in
Chile, control of meningococcal group W [Men W] outbreaks in
Latin America, Men B outbreaks in the United States, and Men A
outbreaks in sub-Saharan Africa).
Representatives were not available from all Asia-Pacific coun-
tries and therefore this article focuses on those present at the
GMI meeting.2.2. Objectives
The specific objectives of the meeting were to: (1) understand
the epidemiology of MD in the Asia-Pacific region over the past
decade; (2) examine the surveillance and prevention strategies in
Asia; (3) discuss key learning points from experience with
meningococcal vaccine programs, and how these may be applied
elsewhere; (4) develop recommendations to improve diagnosis
and surveillance, and for the control and prevention of MD in Asia,
including outbreak preparedness; and (5) devise methods for the
dissemination of information.3. Discussion
3.1. Overview of MD across the globe
The epidemiologic profile of MD varies across the globe; how-
ever, 6 of the 12 recognized serogroups (A, B, C, W, X, and Y) are
known to cause the majority of the disease worldwide [6]. In Eur-
ope and North America, where serogroups B and C predominate,
the disease is endemic, with a low overall incidence (1 per
100,000), characterized by seasonal peaks and small clusters of
cases [7]. By contrast, in the ‘‘meningitis belt” of sub-Saharan
Africa, large periodic epidemics of MD occur frequently with an
incidence that may reach 1000 per 100,000. Most African epi-
demics have been caused by meningococci belonging to serogroup
A, but outbreaks of serogroup C, W, and X disease have also been
recorded [7]. Although epidemiologic data from Asia are limited,
it has been suggested that serogroup A and C predominate; but ser-
ogroup W is increasingly reported in several countries, such as
China [8–10].3.1.1. Latin America
In Latin America, incidence rates and serogroup distribution are
highly variable, with the highest burden of disease reported in Bra-
zil and the Southern Cone countries (Argentina, Chile, and Uru-
guay) [11]. Serogroups B and C are reported to be responsible for
the majority of cases reported in the region, although there has
been a recent increase of serogroup W disease in Argentina, Chile,
and Southern Brazil [11]. In addition, it has been noted that the
carriage data for Men W (cc11) from Chile were similar to the
Men C (cc11) carriage data from the UK before the meningococcal
serogroup C conjugate (MCC) vaccine introduction took place in
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ers of serogroup W in Chile during the outbreak.
Although progress has been made in improving and coordinat-
ing the surveillance of invasive disease in Latin America, there is a
clear need to improve and establish more uniform quality surveil-
lance across the region and standardize case definitions [11]. It is
anticipated that there will be an increased use of the meningococ-
cal quadrivalent conjugate vaccines in the near future, which will
replace polysaccharide vaccines [11]. Three vaccines have been
used in Latin America: an outer membrane vaccine (OMV) + C
polysaccharide, a MCC vaccine, and quadrivalent conjugate (A
+ C + Y + W) vaccine. The OMV + C polysaccharide vaccine has been
part of the routine immunization calendar in Cuba since 1991; it is
administered in 2 doses in children at ages 3 and 5 months. Recent
data suggest that the efficacy of the Cuban vaccine varies by age of
recipient, and may be effective for prevention of serogroup B MD in
older children and adults. The estimated efficacy of the vaccine in
children younger than 24 months was 37% (95% confidence
interval [CI]: <100 to 73); 47% (95% CI: 72 to 84) in children
24–47 months and 74% (95% CI: 16–92) in children 48 months or
older.
In 2010, in response to an outbreak, the MCC vaccine was intro-
duced to the infant calendar in Brazil for all children aged <2 years.
As a consequence, there was an immediate reduction in incidence
rates of MD in children aged <2 years and those 2–4 years. How-
ever, in other age groups the vaccine did not have an early impact,
which likely reflects the lack of a catch-up campaign targeting
older age groups. Due to a notable increase in the number of cases
and deaths due to serogroup W beginning in 2010, the Chilean
health authorities implemented a vaccination campaign with the
tetravalent conjugate vaccine. The vaccine is now part of the
national infant schedule and involves vaccination of children aged
>1 year with a single dose. Although the incidence and mortality
rates of MD in Chile have decreased since the vaccination program
was implemented in 2014, both remain high. Most recent cases are
due to serogroup W and are seen in the urban capital area. The
Latin American experience, specifically the carriage data of Men
W from Chile, demonstrated that adolescents were the main car-
rier pools in the Chilean outbreak. However, no vaccine effective-
ness data were collected and no evidence of herd protection was
observed.
3.1.2. United States
In 2013, 2 universities in the United States responded to out-
breaks of Men B disease with mass vaccination campaigns using
an unlicensed Men B vaccine. Both outbreaks resulted from the
same rare strain of B. Vaccination coverage was high (97% students
received a first dose and 91% received a second dose). To date, the
vaccine effectiveness has not been established. Safety data were
not collected, but it appeared that there was a significant amount
of local site reactogenicity.
In New Jersey, although it was not licensed in the United States
at the time, Bexsero (a serogroup B vaccine) was employed to
control an outbreak at Princeton University that was caused by a
serogroup B ST-409 strain. Vaccine coverage with Bexsero was
high: 97% of undergraduate students received a first dose and
91% received a second dose. Despite this high coverage, nasopha-
ryngeal carriage was not eradicated, since a student at another uni-
versity who came in contact with a vaccinated Princeton student
contracted MD. This was to be expected since this recombinant
vaccine does not eliminate carriage, but prevents new acquisitions
of any meningococci, regardless of serogroup [13]. Safety data were
not collected at the time of the outbreak. In 2014, a new serogroup
B vaccine was licensed, TrumenbaTM; it is a bivalent vaccine and is
licensed as a 3-dose series at 0, 2, and 6 months for those aged 10–
25 years.3.1.3. Europe
The development and introduction of MCC vaccines in several
European countries, Australia and Canada has been associated with
a substantial decline in serogroup C disease [7]. A large part of the
success of MCC vaccines has been attributed to the ability of the
vaccines to reduce carriage and transmission of vaccine-type bac-
teria in the population, thus indirectly reducing disease even
among the unvaccinated [7].3.1.4. Africa
Outbreaks are typically cyclical in Africa, and are primarily
caused by serogroup A. Following international standards, a Men
A conjugate vaccine, MenAfriVac (Serum Institute of India Ltd),
has been successfully developed and licensed. In an effort to elim-
inate meningococcal serogroup A, mass vaccination campaigns
with the vaccine began in 2010 and targeted the 26 countries in
the ‘‘meningitis belt” region of sub-Saharan Africa. By 2014, 153
million people aged 1–29 years had been vaccinated. High cover-
age rates of >90% were achieved in these countries where the vac-
cine was introduced. Notably, pregnant women were included in
the program, and follow-up studies of women and their babies
did not identify any safety concerns [14]. Currently, it is recom-
mended that this finding be added to the package insert of the
MenAfriVac vaccine so that it can be given freely to pregnant
women. Research from recent and ongoing studies suggests that
immunization should start in late infancy (3–24 months, possibly
with polysaccharide A 5-lg dosage). Since the program was imple-
mented, there has been a decrease in the number of meningitis
cases attributable to serogroup A. A herd effect protecting infants
and those aged >30 years has been observed. Due to the mass vac-
cination program, serogroup A carriage has decreased, which
could, in the long run, affect population immunity due to a lack
of natural boosting. In addition, since the introduction of MenAfri-
Vac, the number of meningitis cases – both overall, and in partic-
ular due to serogroup A – has decreased. There has also been a
marked change in the bacteriological cause of meningitis following
vaccine introduction: a larger proportion of meningitis cases are
now due to other serogroups (e.g. W, X, and Y), highlighting the
fact that surveillance to detect other serogroups needs to be
strengthened. This also brings to attention the unmet need for vac-
cines to protect against these other serogroups in this region of
Africa.3.2. Overview of MD in the Asia-Pacific region
3.2.1. China
No representative of China attended the GMI meeting, therefore
this country was not described in-depth previously. However, as a
brief summary, and for completeness, this section has been
included.
In China, serogroup A polysaccharide vaccine was first used in
the routine immunization program; however, the bivalent (A, C)
polysaccharide vaccine was later introduced following a number
of serogroup C outbreaks.
Between 1996 and 2002, there were only 292 reported cases of
MD in Taiwan, of which 158 were culture confirmed [15]. The
majority of these cases were due to serogroup B, but a large pro-
portion was due to serogroup W. In China, shifts in the disease-
causing serogroups have been observed. For example, in a study
carried out in Shanghai, serogroup A was shown to be the predom-
inant serogroup noted for many decades, but in 2005–2013, ser-
ogroups B and C predominated (accounting for 62% of cases)
[16]. Furthermore, prior to 2006, in China, all MD cases were
caused by serogroups A, B, and C; however other serogroups (e.g.
W) have now been reported [9].
5858 R. Borrow et al. / Vaccine 34 (2016) 5855–5862The serogroups associated with outbreaks in China have also
altered over time: while serogroup A was initially the main causa-
tive, serogroup C became of increasing concern following the
implementation of Men A vaccination. However, there have also
been an increasing number of invasive cases caused by serogroups
B and W [9,10,17].Fig. 1. Reported number of invasive MD cases, Japan, April 2013 to August 2014.
Source: National Epidemiological Surveillance of Infectious Diseases (NESID).3.2.2. India
N. meningitidis is the third most common cause of bacterial
meningitis in India in children aged <5 years, and is responsible
for an estimated 1.9% of all cases regardless of age [5]. The majority
of reported cases are due to serogroup A, with rare reports of ser-
ogroups B and C. Since 2002, the number of reported meningitis
cases due to MD in India has decreased markedly, while case fatal-
ity rates have also dropped (from 9.8% to 5.2%).
There has, however, been an increase in the number of MD out-
breaks reported throughout India, with more outbreaks reported in
the temperate northern regions than the tropical southern regions
[5]; the majority of cases occur in late winter and early spring.
Three significant outbreaks have been reported since 2005: in
New Delhi (2005–2009) and, for the first time, in Meghalaya
(2008–2009) and Tripura (2009) in north-eastern India [5]. These
unexpected outbreaks affected treatment because, as clinicians
did not suspect MD, patients were initially treated incorrectly. Also
of note, during recent outbreaks a shift in the affected age group
was observed and for the first time there was an increase in the
proportion of cases in young adults. This observation may suggest
the emergence of a new potentially epidemic clone, against which
the population is immunologically naïve [18].
The New Delhi outbreak from 2005 to 2009 was due to ser-
ogroup A, with the majority (40%) of cases occurring in people aged
15–30 years. The outbreak was concentrated in urban areas and
involved both types of clinical presentations, with cases of menin-
gitis (60%) and meningococcemia (40%) observed. Mass vaccination
was not recommended since there was a low attack rate, the dis-
ease was not focalized, and the quadrivalent vaccine (A, C, W,
and Y), which was used only in vaccination of healthcare practi-
tioners (HCPs), is not known to be effective in children aged
<2 years. Isolation wards were established and cases of meningitis
were managed using third-generation cephalosporins and peni-
cillins. Chemoprophylaxis, using ciprofloxacin, of close contacts
and high-risk groups was implemented. The outbreak was man-
aged through mandatory daily reporting of all probable and lab-
confirmed cases, augmentation of hospital surveillance for early
reporting of cases, strengthening of laboratories and case manage-
ment facilities, and by ‘‘around-the-clock” control rooms, which
were set up to provide information to HCPs and the general public.
The Meghalaya outbreak, which occurred in 2008–2009, also
involved both clinical presentations (meningitis, 60–70%;
meningococcemia, 30–40%). The majority of cases were seen in
people aged 15–49 years, with more than 250 lab-confirmed cases
of Men A. Unfortunately, the health infrastructure in Meghalaya
was not prepared for the outbreak as cases had never before been
seen in the state. Outbreak management involved establishing a
7-day control room in Shillong in order to provide information to
the public and to HCPs, strengthening of case management
facilities in hospitals and lab services at the state level, and
meningococcal vaccination of all HCPs. Chemoprophylaxis of close
contacts of affected people was implemented and mass chemopro-
phylaxis in selected areas was undertaken. Similar to the manage-
ment of cases in the Delhi outbreak, third-generation
cephalosporins were used to treat patients; additional penicillin
or chloramphenicol was used in some hospitals. A mass vaccina-
tion program of the entire populations of the 2 most affected dis-
tricts was carried out in May–June of 2009 using the bivalent (A+ C) meningococcal polysaccharide vaccine, which led to a signifi-
cant reduction in cases; no cases have been reported since 2010.
Similar to the outbreaks in Delhi and Meghalaya, the Tripura
outbreak in 2009 also involved cases of mixed presentation
(meningitis, 60–70%; meningococcemia, 30–40%). The majority of
cases occurred in patients aged 20–30 years and, like the other out-
breaks in India, serogroup A was the dominant causative strain.
Third-generation cephalosporins were again used (with injectable
chloramphenicol used in some hospitals), and most patients
responded rapidly to antimicrobials. Meningococcal vaccination
was implemented for all HCPs. Chemoprophylaxis of close contacts
of affected patients began in early February 2009 and mass chemo-
prophylaxis was implemented in the most affected area, the Dhalai
district, in late February 2009. Mass chemoprophylaxis led to no
reduction in cases. In June–July, a mass vaccination of the entire
population of people aged 2–50 years in the Dhalai district, using
the bivalent (A + C) meningococcal polysaccharide vaccine, led to
a significant reduction in cases; no cases have been reported since
2010. The bivalent polysaccharide vaccine is known to provide pro-
tection lasting 3–5 years.
Reports from India highlight the need for studies to determine
how long antibodies persist post immunization; data from these
studies are critical for countries where outbreaks are cyclical. This
information is also important for formulating vaccination strate-
gies for HCPs who may be repeatedly exposed to MD.
The preparation for an outbreak in India varies between large
cities and remote communities. Whereas in the former, organisms
can be quickly identified and appropriate measures mobilized, this
is not the case in the latter. With help from the US Centers for Dis-
ease Control and Prevention (CDC), many HCPs are being trained in
how to perform surveillance and deal with outbreaks. Units con-
sisting of a microbiologist, an epidemiologist, and a clinician are
described as rapid response teams. However, the major issue in
outbreak preparedness is laboratory diagnostics; these are lacking
at the state level and need to be strengthened.
The decision to undertake mass vaccination following an out-
break is based upon the attack rate within an area. During inter-
epidemic and epidemic periods, immunoprophylaxis of high-risk
populations (e.g. HCPs) is implemented and chemoprophylaxis
with antimicrobials is used for close contacts. In addition, during
epidemic situations, social distancing (closure of schools, colleges,
cinemas, etc.) is used to slow the spread of the disease. However,
the impact and success of social distancing remains uncertain. This
is to be expected given the different capabilities of the different
communities in India: for those living in crowded conditions,
school closure may not have the same impact as on those living
with fewer contacts.
The lack of a strong surveillance system in India appears to have
hampered accurate epidemiologic quantification of the MD burden
Table 1
The epidemiology of MD in the Asia-Pacific region.
Japan India Republic of Korea The Philippines
Quality of data Detection of MD is reliant on clinicians’ ability
to suspect meningococci. Surveillance system
in place and laboratory resources good
Mostly only available during outbreaks Little reliable epidemiologic data Only the septicemic form, meningococcemia, is
reported
Data source NESID 3 recent major outbreaks (Delhi/NCR [2005],
Meghalaya [2008–2009] and Tripura [2009])
KCDC, HIRA and individual
published reports
PIDSR
Incidence 0.027/100,000 during April 2013 to Aug 2014 Not reliably known 0.012–0.05/100,000/year in the
general population (KCDC and
HIRA data)
0.02–0.1/100,000/year
6.8/100,000/year in children aged
<5 years (CSF PCR study data)
Age groups affected Since April 2013, MD has become more
prevalent in elderly individuals due to a
change in surveillance
An increase in the proportion of cases in young
adults has recently been reported
Varies across the 3 reporting
systems
The number of cases was greatest in infants and
young children (case fatality high; females more than
males)
Predominant
serogroups
Serogroup Y, followed by C and B (but these
data are based on only 59 cases)
Serogroup A with rare reports of B and C No predominant serogroups at this
time
Serogroup A, although B has been documented
Case definition MD with either culture- or PCR-positive cases,
using blood or CSF sample, are confirmed cases
and need to be reported as soon as diagnosed
Suspect: Sudden onset of fever >38.5 C rectal or
38.0 axillary with stiff neck or bulging fontanel in
patients aged <1 year
Differ depending on location and
situation, i.e. outbreak definition
different from non-outbreak
situations
Suspect: Acute fever with hemorrhagic rash and/or
meningeal signs
Probable: Suspect case as defined above, with Gram
stain showing diplococci or ongoing epidemic or
purpural rash
Probable: A suspect case with turbid CSF or Gram-
negative diplococci from CSF, blood, skin, or close
contact with a confirmed case during the previous
10 days
Confirmed: suspect or probable case as above, with
either positive CSF/blood culture or positive CSF
antigen detection for meningococcus or positive PCR
test
Confirmed: A suspect case with N. meningitidis
isolated from a sterile site (CSF, blood, skin) or
presence of N. meningitidis DNA from a sterile site
(CSF, blood, skin)
CSF, cerebrospinal fluid; DNA, deoxyribonucleic acid; HIRA, Health Insurance Review and Assessment Service; KCDC, Korea Centers for Disease Control and Prevention; MD, meningococcal disease; NCR, National Capital Region;
NESID, National Epidemiological Surveillance of Infectious Disease; PCR, polymerase chain reaction; PIDSR, Philippine Integrated Disease Surveillance and Response.
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Fig. 2. Different incidence rates of MD, depending on reporting system. Sources: KCDC data from Disease Web Statistics System, KCDC (http://is.cdc.go.kr/dstat/index.jsp).
HIRA data from Statistics Service, HIRA (http://www.hira.or.kr/main.do).
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disease. As a consequence, it is likely that MD is markedly under-
reported in India. Furthermore, much of the epidemiologic data
that are available have been collected during outbreaks [6] and,
as such, the experts (epidemiologists, microbiologists, and clini-
cians) tend to collaborate only during these epidemics. Case defini-
tions employed in India are based on the World Health
Organization (WHO) guidelines. Moreover, polymerase chain reac-
tion (PCR) methods for accurate detection of the bacterium are
only performed on special request or if a study is being undertaken.
During inter-epidemic periods, data are collected from the Central
Bureau of Health Intelligence (CBHI), Integrated Disease Surveil-
lance Project, and individual published reports. However, the data
may be incomplete or inaccurate since many patients receive
antibiotics from their HCP if MD is suspected, and this tends to
occur before hospital admission. Another variable that results in
underreporting is that some patients die from complications with-
out being seen by an HCP or at a hospital early in the course of MD.3.2.3. Japan
Japan is exceptional in that it has an estimated low incidence of
MD (Fig. 1). For the last few decades, the only outbreak in Japan
was caused by serogroup B and occurred in a high-school dormi-
tory (May 2011). From 1999 to 2013, the number of cases of MD
was highest in adolescent males (59% of total cases). Since 2013,
the proportion in males has increased to 69% of total cases andFig. 3. MD cases by age group and sex in the Philippines, 2013 (N = 182). Sources:
Philippine Integrated Disease Surveillance and Response (PIDSR) Annual Report
2013, the National Epidemiology Center of the Department of Health (http://
www.doh.gov.ph/nec-orgchart). Available from: https://xa.yimg.com/kq/groups/
85999055/777284928/name/pidsr2013.pdf.the age cohort effect shifted (Table 1). In order of frequency, the
major serogroups isolated were Y, C, and B (Table 1).
Surveillance in Japan is undertaken by the National Epidemio-
logical Surveillance of Infectious Diseases (NESID). Since 1999, only
meningitis cases have been reported and data are collected on the
detection/isolation of meningococci from patients with meningitis.
From April 2013, in addition to meningococcal meningitis,
meningococcal bacteremia without focus has been added to the list
of notifiable diseases as an invasive MD. In Japan, detection of MD
is dependent upon the clinicians’ ability to suspect meningococci.
Following confirmation of N. meningitidis, the disease is reported
to the local health department. For more detailed testing, the sam-
ple may be sent to the National Institute of Infectious Diseases
(NIID) or local public health laboratory (NESID).
MD outbreaks are relatively rare in Japan. However, in August
2015, several European children were diagnosed with serogroup
W MD following their return from a World Scout Jamboree in
Japan. No Japanese inhabitants were affected and the strain
involved had been reported since 2009 in the UK [19].
Immunization is not obligatory in Japan, but individuals may be
vaccinated upon request based on the national recommendations.
From 2015, the tetravalent meningococcal (ACYW) conjugate vac-
cine (MCV4) has been available, although it is a voluntary vaccine
and only available for private purchase. While serogroup B has
been detected, it is unclear when the vaccine against MD serogroup
B will be licensed in Japan.
To improve preparedness in Japan, 3 aspects must be improved:
raise awareness of MD among HCPs, determine the true burden of
disease in the country, and educate HCPs on how to use the vaccine
in outbreak settings.3.2.4. Republic of Korea
There is a paucity of reliable epidemiologic data from the
Republic of Korea; although the reporting of meningococcal
meningitis cases is mandatory, MD surveillance is passive and
reporting varies across medical facilities. There are 3 main sources
of surveillance data: the central laboratory (Korea Centers for Dis-
ease Control and Prevention [KCDC]), the Health Insurance Review
and Assessment Service (HIRA), and individual report papers. Data
reported by these sources vary widely (Fig. 2), as do impacted age
cohorts and incidence rates (Table 1). In addition, bacterial culture
is the most commonly used diagnostic method, and it may be com-
promised by prior antibiotic use, which is prevalent countrywide.
There are no guidelines for the management of MD outbreaks in
the Republic of Korea. Importantly, it is thought that there is a risk
Table 2
GMI recommendations for the Asia-Pacific region.
GMI Recommendations
 Strengthen surveillance systems
 Standardize case definitions, including all clinical forms and not only meningitis
 Centralize reporting
 Develop guidelines on how to diagnose MD in different settings (based on resources available)
 Improve matching between epidemiologic and laboratory data (i.e. capture-recapture studies)
 Develop guidelines on how to detect and manage outbreaks
 Increase awareness of MD among HCPs and health authorities – regional and global networking
 Identify which cohorts asymptomatically carry meningococci – crucial for controlling transmission of MD and ensuring herd protection
GMI, Global Meningococcal Initiative; HCP, healthcare practitioner; MD, meningococcal disease.
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protection.
The last outbreak in the Republic of Korea was in 2011 in the
Korean Army; although outbreaks are rare, close contacts always
receive chemoprophylaxis. The emphasis is on attempting to
determine who is at high risk of infection. To improve prepared-
ness in the Republic of Korea, surveillance systems need to be
improved and outbreak guidelines specific for MD should be devel-
oped. It was suggested that the establishment of reporting systems
with a reference center would allow HCPs who are recognized as
having expertise for MD to send alerts that could increase the
interest and awareness of the health authorities.3.2.5. The Philippines
According to data reported to the Philippine Integrated Disease
Surveillance and Response (PIDSR) group, which was created in
2005 in response to the International Health Regulations of the
WHO from 2008 through 2013 the number of meningococcemia
cases in the Philippines increased from 73 in 2008 to 182 in
2013. PIDSR is an enhanced surveillance system, which monitors
notifiable diseases and other health-related events of public health
importance using an integrated approach.
Surveillance for bacterial meningitis has been adopted by the
National Epidemiology Center as a surrogate for Invasive
Bacterial-Vaccine Preventable Disease; however, only the sep-
ticemic form, meningococcemia, is reported to the surveillance
and response systems in the Philippines. As a consequence of this,
data are skewed to reflect a high case fatality rate and are extre-
mely unlikely to report the true burden of meningitis.
Surveillance of MD is based on clinical case definitions that can
be used in all types of healthcare settings. For confirmation of MD,
PCR is mostly used in the central laboratory but is also available in
local hospitals.
An average of 100 cases is reported every year without seasonal
variation (Table 1). The number of cases is greatest in infants and
young children, and the case fatality rate is highest among infants
(P50%). The incidence tended to be higher among males than
females (Table 1; Fig. 3). Serogroup A predominates, although ser-
ogroup B has been documented in the past.
During the 2004/2005 outbreak in the Cordillera Administrative
Region, 2 vaccines were used: the bivalent polysaccharide A and C
vaccine, which was used extensively; and the tetravalent polysac-
charide vaccine. The target group for mass vaccination was initially
children aged 2–8 years. Vaccination target groups were later
expanded and included grade school children and local healthcare
workers.
Meningococcal vaccines are not part of the Philippine Expanded
Program on Immunization, but available data support their use in
certain conditions or selected populations. Two meningococcal
vaccines are available, the MCV4 and the tetravalent meningococ-
cal polysaccharide vaccine (MPSV4).3.3. Achievements and remaining challenges in the Asia-Pacific region
In the Asia-Pacific region, there are limited data and many
improvements are needed. In addition, the incidence of MD varies
substantially between countries, and this may not be a true reflec-
tion of the disease prevalence in this region. For example, Japan
and the Republic of Korea have frequently reported a low incidence
of MD, while India by comparison has a higher incidence of disease.
Costs have been suggested as an explanation for the lack of data
gathering; however, logistic issues may also play a role. For
instance, in India it was noted that sample flow was erratic and
therefore it was difficult for the laboratories to maintain the
required reagents. Moreover, diagnostic guidelines need to be
implemented and reference laboratories established that can
maintain the awareness and quality of PCR as a diagnostic tool.
Laboratory-based surveillance for MD should be strengthened or
initiated in Asia-Pacific countries to determine the true disease
burden.
Immunization with the polysaccharide and conjugate vaccines
in this region has highlighted the importance of carriage studies
in understanding disease transmission. The polysaccharide vaccine
is very poor at disrupting carriage, while the conjugate vaccine dis-
rupts acquisition of carriage. The GMI outlined the importance of
quality control of carrier studies to ensure reliability of the data.
3.4. Recommendations for the control and prevention of
meningococcal disease in the Asia-Pacific region
Based on the discussions during the meeting, the GMI made a
number of key recommendations that will lead to better under-
standing of MD and reduce its public health impact in the Asia-
Pacific region (Table 2).
It was generally accepted that the incidence rates in the Asia-
Pacific region do not reflect the true burden of MD and, as such,
there is a need to improve case reporting and standardize case def-
initions. The GMI recommended the development of new guideli-
nes to aid the diagnosis of MD. It was felt that surveillance
systems need to be strengthened across the region, especially in
countries were there have been several recent outbreaks, e.g.,
India. The development of outbreak management guidelines,
including a definition of the term ‘‘close contact,” was seen as
essential. The GMI felt that targeting vulnerable group(s) for vacci-
nation during outbreaks would be critical for disease control. In
addition, the GMI emphasized the need to undertake inter-
epidemic carriage studies in order to determine which cohorts
(i.e., age groups) asymptomatically carry meningococci, as these
studies would be crucial in controlling the transmission of MD
and ensuring herd protection.
Finally, it is vital to increase awareness of MD among HCPs and
public health authorities. Improving interactions with decision-
makers and recommendation committees was deemed of great
importance for improving awareness of the disease and in ensuring
5862 R. Borrow et al. / Vaccine 34 (2016) 5855–5862that MD prevention and management initiatives have the
resources they need. It was noted that the GMI members could
reach out to funding bodies/apply for grants for training courses
on areas of importance, such as PCR training.
4. Summary and conclusions
Based on the surveillance, diagnosis, and confirmation data pre-
sented at this meeting, the incidence of MD in the Asia-Pacific
region appears to be low; however, these data may not be a true
reflection of disease prevalence across the region. The reasons for
this appear to be multifactorial and include underreporting, weak
surveillance systems, lack of guidelines, inconsistent case defini-
tions, and varying awareness of MD. Indeed, in the Republic of
Korea, data discrepancies between the different surveillance sys-
tems employed emphasize this point and suggest potential under-
reporting of MD in the country by some systems.
In order to better understand the epidemiology of MD in the
Asia-Pacific region, the GMI has developed a number of recommen-
dations, including strengthening surveillance, developing diagno-
sis and management guidelines, and increasing disease awareness.
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